BrainStorm Cell Therapeutics Inc. (BCLI) Sets New 12-Month High at $3.87
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s share price reached a new 52-week high on Friday . The stock traded as high as $3.87 and last traded at $3.14, with a volume of 3,094,755 shares changing hands. The stock had previously closed at $3.56.
Separately, Maxim Group restated a “buy” rating and set a $5.00 price objective on shares of BrainStorm Cell Therapeutics in a research report on Wednesday, May 11th.
The company has a 50-day moving average of $2.48 and a 200 day moving average of $2.42. The stock’s market capitalization is $55.78 million.
BrainStorm Cell Therapeutics (NASDAQ:BCLI) last issued its earnings results on Tuesday, May 10th. The biotechnology company reported ($0.10) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.15. On average, equities analysts predict that BrainStorm Cell Therapeutics Inc. will post ($0.58) EPS for the current year.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.